Tetravalent Antibody–scTRAIL Fusion Proteins with Improved Properties
Publication type: Journal Article
Publication date: 2014-01-01
scimago Q1
wos Q1
SJR: 2.493
CiteScore: 11.0
Impact factor: 5.5
ISSN: 15357163, 15388514
PubMed ID:
24092811
Cancer Research
Oncology
Abstract
We applied the immunoglobulin E (IgE) heavy-chain domain 2 (EHD2) as the covalently linked homodimerization module to generate antibody–scTRAIL fusion proteins. By fusing a humanized single-chain fragment variable (scFv) directed against EGFR to the N-terminus of the EHD2 and a single-chain derivative of TRAIL (scTRAIL) to the C-terminus of the EHD2, we produced a dimeric, tetravalent fusion protein. The fusion protein retained its binding activity for EGFR and TRAIL receptors. In vitro, the targeted antibody–scTRAIL fusion protein exhibited an approximately 8- to 18-fold increased cytotoxic activity compared with the untargeted EHD2-scTRAIL fusion protein. This resulted in increased antitumor activity in a subcutaneous Colo205 xenograft tumor murine model. In summary, the scFv-EHD2-scTRAIL fusion protein combines target cell selectivity with an increased TRAIL activity leading to improved antitumor activities. Mol Cancer Ther; 13(1); 101–11. ©2013 AACR.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
4
|
|
|
mAbs
4 publications, 9.76%
|
|
|
Scientific Reports
3 publications, 7.32%
|
|
|
Oncotarget
2 publications, 4.88%
|
|
|
Cancers
2 publications, 4.88%
|
|
|
Molecules
2 publications, 4.88%
|
|
|
Frontiers in Immunology
2 publications, 4.88%
|
|
|
Cell Death and Differentiation
2 publications, 4.88%
|
|
|
Journal of Controlled Release
2 publications, 4.88%
|
|
|
Proceedings of the National Academy of Sciences of the United States of America
2 publications, 4.88%
|
|
|
Frontiers in Pharmacology
1 publication, 2.44%
|
|
|
BioSpektrum
1 publication, 2.44%
|
|
|
Drug Discovery Today
1 publication, 2.44%
|
|
|
Cancer Letters
1 publication, 2.44%
|
|
|
Arthritis and Rheumatology
1 publication, 2.44%
|
|
|
Journal of Interdisciplinary Nanomedicine
1 publication, 2.44%
|
|
|
Bioconjugate Chemistry
1 publication, 2.44%
|
|
|
International Review of Cell and Molecular Biology
1 publication, 2.44%
|
|
|
OncoImmunology
1 publication, 2.44%
|
|
|
Methods in Enzymology
1 publication, 2.44%
|
|
|
Science
1 publication, 2.44%
|
|
|
bioRxiv
1 publication, 2.44%
|
|
|
Molecular Cancer Therapeutics
1 publication, 2.44%
|
|
|
eLife
1 publication, 2.44%
|
|
|
Journal of Drug Delivery Science and Technology
1 publication, 2.44%
|
|
|
Antibody Therapeutics
1 publication, 2.44%
|
|
|
Cancer Medicine
1 publication, 2.44%
|
|
|
Russian Chemical Reviews
1 publication, 2.44%
|
|
|
International Journal of Pharmaceutics
1 publication, 2.44%
|
|
|
1
2
3
4
|
Publishers
|
1
2
3
4
5
6
7
8
|
|
|
Elsevier
8 publications, 19.51%
|
|
|
Springer Nature
6 publications, 14.63%
|
|
|
Taylor & Francis
5 publications, 12.2%
|
|
|
MDPI
4 publications, 9.76%
|
|
|
Frontiers Media S.A.
3 publications, 7.32%
|
|
|
Wiley
3 publications, 7.32%
|
|
|
Impact Journals
2 publications, 4.88%
|
|
|
Cold Spring Harbor Laboratory
2 publications, 4.88%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
2 publications, 4.88%
|
|
|
American Chemical Society (ACS)
1 publication, 2.44%
|
|
|
American Association for the Advancement of Science (AAAS)
1 publication, 2.44%
|
|
|
American Association for Cancer Research (AACR)
1 publication, 2.44%
|
|
|
eLife Sciences Publications
1 publication, 2.44%
|
|
|
Oxford University Press
1 publication, 2.44%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 2.44%
|
|
|
1
2
3
4
5
6
7
8
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
41
Total citations:
41
Citations from 2024:
7
(17%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Seifert O. et al. Tetravalent Antibody–scTRAIL Fusion Proteins with Improved Properties // Molecular Cancer Therapeutics. 2014. Vol. 13. No. 1. pp. 101-111.
GOST all authors (up to 50)
Copy
Seifert O., Plappert A., Fellermeier S., Siegemund M., Pfizenmaier K., Kontermann R. E. Tetravalent Antibody–scTRAIL Fusion Proteins with Improved Properties // Molecular Cancer Therapeutics. 2014. Vol. 13. No. 1. pp. 101-111.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1158/1535-7163.mct-13-0396
UR - https://doi.org/10.1158/1535-7163.mct-13-0396
TI - Tetravalent Antibody–scTRAIL Fusion Proteins with Improved Properties
T2 - Molecular Cancer Therapeutics
AU - Seifert, Oliver
AU - Plappert, Aline
AU - Fellermeier, Sina
AU - Siegemund, Martin
AU - Pfizenmaier, Klaus
AU - Kontermann, Roland E.
PY - 2014
DA - 2014/01/01
PB - American Association for Cancer Research (AACR)
SP - 101-111
IS - 1
VL - 13
PMID - 24092811
SN - 1535-7163
SN - 1538-8514
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2014_Seifert,
author = {Oliver Seifert and Aline Plappert and Sina Fellermeier and Martin Siegemund and Klaus Pfizenmaier and Roland E. Kontermann},
title = {Tetravalent Antibody–scTRAIL Fusion Proteins with Improved Properties},
journal = {Molecular Cancer Therapeutics},
year = {2014},
volume = {13},
publisher = {American Association for Cancer Research (AACR)},
month = {jan},
url = {https://doi.org/10.1158/1535-7163.mct-13-0396},
number = {1},
pages = {101--111},
doi = {10.1158/1535-7163.mct-13-0396}
}
Cite this
MLA
Copy
Seifert, Oliver, et al. “Tetravalent Antibody–scTRAIL Fusion Proteins with Improved Properties.” Molecular Cancer Therapeutics, vol. 13, no. 1, Jan. 2014, pp. 101-111. https://doi.org/10.1158/1535-7163.mct-13-0396.